Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial

By sjmartinez • December 3, 2024

Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial. Arthritis Rheumatol. 2024 Dec 3. doi: 10.1002/art.43072. Epub ahead of print. PMID: 39624016.

Tags: Publications, Rheumatology

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]

Effect of biologic use on the development of psoriatic arthritis: A population-based study

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately in a probability-based internet panel

Hays RD, Herman PM, Rodriguez A, Slaughter M, Zeng C, Edelen MO. Correction: The PROMIS-16 reproduces the PROMIS-29 physical and mental health summary scores accurately[...]